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C-Reactive Protein Colocalizes With 
Complement in Human Hearts During 
Acute Myocardial Infarction
Wira K. Lagrand, MD; Hans W.M. Niessen, MD, PhD; Gert-Jan Wolbink, MD; 
Lies H. Jaspars, MD, PhD; Cees A. Visser, MD, PhD; Freek W.A. Verheugt, MD, PhD; 
Chris J.L.M. Meijer, MD, PhD; C. Erik Hack, MD, PhD
B ackground  Rises in circulating C-reactive protein (CRP), 
the prototypical acute-phase protein in humans, correlate with 
clinical outcome in patients with myocardial ischemia and in­
farction. W e hypothesized that these correlations might reflect 
active participation of CRP in the local inflammatory response 
ensuing in the jeopardized myocardium because on binding to a 
ligand, CRP is able to activate the classic pathway of comple­
ment, and in addition, complement activation has been shown to 
occur locally in infarcted myocardium.
M ethods and  R esu lts  To verify our hypothesis, we investi­
gated localization o f  CRP in relation to deposition of complement 
in tissue specimens of infarcted and healthy heart tissue obtained 
from 17 patients who had died after acute myocardial infarction. 
CRP was found to be deposited only in infarcted regions and not 
in normal-appearing areas o f the myocardium, being colocalized
Impaired perfusion of the myocardium results in a local inflammatory response1*2 that comprises a complicated interaction between ischemic myocar­dial and inflammatory cells, cytokines, complement fac­
tors, and acute-phase proteins. The impact of inflam­
mation on the extent of tissue damage after myocardial 
ischemia and infarction in humans is not clear. However, 
studies in animals have shown that local inflammatory 
reactions may contribute significantly (up to 65%) to 
infarct size.!-3 
Inherent to the inflammatory process is the occurrence 
of an acute-phase response.4'6 This response is induced 
by proinflammatory cytokines, which are released from 
the inflamed tissue by inflammatory and/or parenchymal 
cells7-8 and stimulate the liver to synthesize a number of 
acute-phase proteins.9 CRP is regarded as the prototype 
of acute-phase proteins in humans. Circulating levels of 
CRP have been shown to increase in patients suffering 
from AMI.5>6 The physiological role of CRP is not fully
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with depositions of C4 and C3 activation fragments of the com- 
plement system. Deposition of CRP and complement in infarcted 
myocardium appeared to be time dependent, because it was found 
in all infarctions except for one of young age (<12 hours old) 
and two of greater age (> 1  year old), whereas another tissue 
specimen of an infarct <12 hours old showed only moderate but 
positive staining for both CRP and complement in comparison 
with older infarctions.
Conclusions W e conclude that in humans, CRP may local­
ize in infarcted heart tissue and suggest that this acute-phase 
protein promotes local complement activation, and hence tissue 
damage, in acute myocardial infarction. (C irculation, 1997;95: 
97-103.)
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understood; it was discovered by its ability to bind to 
pneumococcal C-polysaccharide,10 but various other 
anti-inflammatory and proinflammatory functions of 
CRP have been described as well.11*15 One of the proin­
flammatory properties observed in vitro is the ability of 
CRP to activate complement via the classic pathway.13-15 
This has led to the hypothesis that after tissue injury, 
CRP binds to damaged cells and, by activating comple­
ment, may contribute to the inflammatory response,13-16 
In agreement with this, CRP has been found to be lo­
calized in inflamed tissues,17*18 including infarcted 
myocardium in rabbits.19*20 In clinical studies, circulat­
ing levels of CRP were found to correlate with total 
infarct size in AMI6 and with prognosis in unstable an­
gina.21 Yet, direct evidence that CRP participates in the 
local inflammatory response of human AMI is lacking, 
although local complement activation has been shown 
to occur in this condition.22-23
To examine a possible role of CRP in the local inflam­
matory reactions ensuing in infarcted human myocar­
dium, we investigated the localization of CRP in relation 
to deposition of activated complement in infarcted human 
heart tissue. To this end, immunohistochemical studies 
were performed using tissue specimens obtained from 17 
patients who died after AML
Methods
i
Patients
All patients included in this study had recently died and were 
referred to the department of pathology for autopsy within 24 
hours after death. Patients were included in the study when at 
autopsy they showed signs of a recently developed AMI, ie, de-
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Selected Abbreviations and Acronyms
AMI = acute myocardial infarction
CRP = C-reactive protein
DAB =  3,3'-diaminobenzidine tetrahydrochloride
LDH = lactate dehydrogenase
MAb =  monoclonal antibody
PMN = polymorphonuclear leukocyte
creased LDH staining (decoloration) of the affected myocardium 
on histochemical examination. Patients did not necessarily have 
clinical evidence of AMI shortly before death, that is, specific 
ECG criteria or a rise in cardiac enzymes (serum creatine kinase 
and serum creatine kinase MB fraction). The study protocol was 
approved by the ethics committee of the Free University Hospital 
Amsterdam.
Processing of Tissue Specimens
Specimens were obtained from the infarcted myocardium as 
well as from adjacent sites. The latter sites showed normal LDH 
staining and were studied as internal controls. Tissue specimens 
were stored at — 196°C (in liquid nitrogen) before being prepared 
as frozen sections. The glass slides used for microscopy were 
pretreated with 0.1% poly-L-lysine (Sigma Chemical Co) to en­
hance adherence of the frozen tissue sections.
Antibodies
An MAb (MAb 5G4) against CRP was obtained by fusing 
spleen cells from a mouse immunized with human CRP with 
SP2/0 cells as described by Wolbink and colleagues.24 The MAbs 
against complement factors used in this study have been de­
scribed25-26 and are summarized in Table I, MAbs were purified 
from hybridoma culture supernatant or ascitic fluid by protein G 
or A chromatography (Pharmacia Fine Chemicals) and stored at 
1 mg/mL in PBS.
Immunohistochemistry
Frozen sections of 4 /¿m were mounted onto glass slides, dried 
for 1 hour by exposure to air, and fixed in acetone (Baker Ana­
lyzed Reagent, Mallinckrodt Baker BV). After a rinse in PBS, 
they were incubated with normal rabbit serum (Dakopatts A/S) 
diluted 1 to 50 in PBS containing 1% wt/vol BSA (PBS-BSA) 
(BSA from Boehringer Mannheim GmbH) at room temperature 
for 10 minutes. The slides were then incubated for 60 minutes 
with specific antibody solutions (each MAb at a 1 to 5000 dilution 
in 1% wt/vol PBS-BSA, except for MAbs C4-1 and 5G4S which 
were diluted 1 to 500). In control experiments, similar incuba­
tions were performed with two irrelevant mouse monoclonal an­
tibodies; IgGl (anti-phospholipase A2, kindly provided by Dr 
F.B. Taylor, Jr, Oklahoma Medical Research Foundation, 
Oklahoma City) and mouse myeloma protein, MOPC 21 (Cappel, 
Organon Teknika) as well as with an irrelevant IgG2a MAb 
(against placental alkaline phosphatase). The slides were washed 
for 30 minutes with PBS and incubated with horseradish 
peroxidase-conjugated rabbit anti-mouse immunoglobulins (RaM- 
HRP, Dakopatts) diluted 1 to 25 in 1% wt/vol PBS-BSA. There­
after, the slides were washed again in PBS; incubated for 4 
minutes in 0.5 mg/mL DAB (Sigma) in PBS, pH 7.4, containing 
0.01% voVvol H20 2; washed again; counterstained with hema­
toxylin for 40 seconds; dehydrated; cleared; and finally mounted.
To match depositions of CRP and complement in the myocar­
dial tissue, double stainings for CRP and C3d or CRP and C4d, 
respectively, were performed. The anti-CRP MAb 5G4 and the 
complement MAbs belong to different IgG subclasses (see Table 
1). Therefore, double staining was performed with goat anti­
mouse IgGl and goat anti-mouse IgG2a. Frozen sections (air- 
dried and acetone-fixed) were preincubated with normal goat se­
rum (diluted 1 to 20) as described above for normal rabbit serum. 
The sections were then incubated with appropriate mixtures of 
MAbs: 5G4 diluted 1 to 50 and C4-4, 1 to 5000; or 5G4, 1 to 50
and C3-15, 1 to 5000. After a washing with PBS, the slides were 
incubated simultaneously with horseradish peroxidase-conju­
gated goat anti-mouse lgG2a and biotin-conjugated goat anti- 
mouse IgGl (Southern Biotechnology Associates Inc), both di­
luted 1 to 50. The complement MAbs were then visualized by 
incubation of the slides with streptavidin-alkaline-phosphatase 
complex (1000 U/mL) diluted 1 to 250 (Boehringer), followed 
by exposure of the slides to naphthol AS-MX and fast blue BB 
base (both from Sigma). The CRP/5G4 MAb was demonstrated 
by exposure of the slides to the DAB solution as described above 
for the single staining procedure. For all myocardial tissue spec­
imens, the age of the AMI was estimated by microscopic crite­
ria,27*28 which included intensity of eosinophilic staining of in­
volved myofibers, loss of nuclei and cross-striation, PMN and 
lymphocyte infiltration, and fibrosis. All slides were judged by 
three independent investigators (W.K.L., H.W.M.N., and L.H.L), 
each scoring for infarct age and anatomic localization of specific 
antibody as visualized by immunohistochemical staining. The an­
atomic localizations examined were the myofiber (membrane, cy­
toplasm, nucleus, cross-striations) and blood-vessel elements (en­
dothelium and surrounding tissue). Distinctions were made 
between negative, moderate positive, and strong positive immu- 
nostaining. In addition, the presence of PMN or lymphocyte in­
filtration was scored for. For the final scoring results, consensus 
was achieved by the three investigators.
Results
Patients
Myocardial tissue specimens were obtained from 17 pa­
tients who had died after AMI, as shown by autopsy per­
formed within 24 hours after death. Except for 4 patients 
(patients 4, 6, 12 [streptokinase], and 17 [coronary sur­
gery], Table 2), none of the patients had received reper­
fusion therapy. Three patients (patients 1, 3, and 11) had 
a history of previous AMI, Most patients had a posterior 
wall infarction, but other locations were involved as well 
(Table 2). Specimens were obtained from the infarcted 
myocardium as well as from normal-appearing myocardial 
tissue. The age of the infarct, assessed by use of micro­
scopic criteria described before,27'28 varied from <12 
hours up to > 2  weeks (Table 2). From patients 1 and 11, 
tissue specimens were also taken from the old, fibrotic 
myocardial infarction sites (anamnestically 1 and 10 years 
old, respectively).
Localization of CRP
By immunohistochemistry, CRP was found to be local­
ized in 16 of the 17 myocardial infarctions studied. An 
example of the observed staining patterns is given in Fig 
1 A, which shows positive CRP staining in infarcted myo­
cardial tissue. In most infarctions, CRP was found to be 
localized on the jeopardized myofibers. Except for 1 sec­
tion with moderate and 3 with strong positive immuno- 
staining, CRP was not found to be located on blood ves­
sels. The overall results and the intensity of the 
immunostaining for CRP are listed in Tables 3 and 4» re-
T a b l e  1. Antibodies Used for Immunohistochemical 
Examination
MAb Antigen Antibody Subclass
5G4 G-reactive protein lgG-2a
C4-4 C4d lgG-1
C4-1 C4c lgG-1
C3-15 C3d lgG-1
C3-9 C3c lgG-2a
C3-5 C3a lgG-1
T a b le  2. Patient Characteristics
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Patient Sex Age, y
Reason for 
Admittance Cause of Death
History 
of AMI Sites of Recent AMI
Reperfusion 
Therapy for 
Recent AMI
Age of 
Recent 
AMI
% Jeopardized 
Myofibers in 
HE Staining
1 M 81 AMI AMI ++ PW — <12 h ■—
2 M 51 AMI/pneumonia AM l/lung emphysema — PW — <12 h —
3 M 61 Triple arthrodesis AMI + PW/LW/AW — 12-24 h 50
4 M 60 AMI AMI — PW/LW/AW/septal +, SK 1-3 d 60
5 F 69 AMI AMI — PW/RV/septal — 1-3 d 60
6 F 58 AMI AMI/AVS — AW/septa! +, SK 1-3 d 50
7 F 62 Coronary surgery AMI, postoperative — AW/PW/septal — 3-5 d 25
8 M 75 AMI AMI — AW/PW/septal — 3-5 d 65
9 M 75 AMI AMI+tamponade — PW — 3-5 d 65
10 F 54 AMI AMI/DIC — PW/RV — 5-9 d 70
11 M 63 AMI AMI/AAAA + + AW — 5-9 d 20
12 M 70 AMI AMI — PW/RV +, SK 5-9 d 20
13 M 80 AMI AMI+tamponade — LW — 5-9 d 40
14 F 82 AMI/AVR AMI — septal — 5-9 d 25
15 M 63 AMI AMI/CVA — LW/PW — 9-14 d 50
16 M 66 AMI AMI — AW/PW/septal — 9-14 d 60
17 M 53 AMI due to 
aortic dissection 
type A
AMI due to aortic 
dissection type A
PW/RV/septal +, surgery 9-14 d 80
HE indicates hematoxylin-eosin staining (in LDH-unstained sites; estimation of percentage of jeopardized myofibers by area of eosinophilia in frozen 
tissue sections); AVR, aortic valve replacement; AVS, aortic valve stenosis; DIC, diffuse tntravascular coagulation; AAAA; acute abdominal aortic aneurysm; 
CVA, cerebrovascular accident; PW, posterior wall; LW, lateral wall; AW, anterior wall; RV, right ventricle; +, 1 AMI in history; ++, >1 AMI in history; and 
- ,  no AMI in history.
spectively. Remarkably, CRP was not detected in the tis­
sue samples from one patient (patient 1) with the most 
recent AM I (infarct age, between 0 and 12 hours). The 
tissue sample from patient 2 (infarct age, also between 0 
and 12 hours) showed positive staining for CRP but not as 
distinct as seen in the older myocardial infarctions (1 to 
14 days old). In the internal control samples of patients 1 
and 11, remnants of old myocardial infarction (anamnes- 
tically, 1 or 10 years old, respectively) were seen, char­
acterized by fibrotic parts in the remaining myocardium, 
These sites also did not show any staining for CRP. How­
ever, in addition to a negative staining in the 10-year-old 
myocardial infarction site, a strong, positive staining was 
found for CRP in the tissue specimen taken from the recent 
myocardial infarction site in patient 11 (between 5 and 9 
days old). In samples from early infarctions, that is, < 24  
hours old, the sarcolemma of the myofibers was stained 
more distinctly. Staining of cytoplasm of the myofibers, in
addition to that of the sarcolemma, was seen most clearly 
in the older infarct samples (age, > 2 4  hours). No positive 
staining was found for nuclear elements. Cross-striation 
stained for CRP in 10 of 17 of the infarct samples.
We included a number of controls to check the speci­
ficity of the observed staining for CRP. The LDH-un- 
stained (ie, infarcted) myocardial samples contained vari­
ous amounts (20% to 80%, see Table 2) of apparently 
normal, healthy cardiomyocytes. These normal-appearing 
areas in the infarct region did not show any significant 
staining for CRP (see, for example, Fig 1 A). The internal 
controls, taken from the noninfarcted (ie, the LDH- 
stained) sites of myocardium from the same patient, also 
did not show any positive staining for CRP. Significant 
staining seemed to be independent of the presence of PM N 
and/or lymphocyte infiltration. In addition, a similar stain­
ing procedure pexformed with an irrelevant IgG2a MAb 
yielded negative results with all tissue specimens (data not
Fig 1 . Immunohistochemical localization of CRP (A) and complement activation fragment C3d (B) in infarcted myocardium (I indicates 
infarcted and N, normai/noninfarcted myocardium) with MAbs 5G4 and C3-15, respectively, as described in “Methods” (patient 13 
[Table 2], frozen tissue sections from the same myocardial infarction site). Similar staining patterns were seen for CRP and C3d in 
fibers of infarcted myocardium. C3d was also localized in vascular elements (arrows) (magnification X100).
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T a b le  3. Localization of CRP and Complement in 
Myocardial Infarction
Anatomic Localization (No. Positive/Total)
Antigen Myofiber Blood Vessel Myofiber-J-Blood Vessel
CRP 16/17 4/17 4/17
C4d 15/17 12/17 11/17
C4c 11/17 5/17 5/17
C3d 16/17 15/17 15/17
C3c 13/15* 6/15* 6/15*
C3a 0/17 0/17 0/17
Two slides neglected because of high background staining invalidating 
proper immunohistochemical scoring procedure,
shown). Staining for CRP of myocardial tissue specimens 
obtained from a patient who died of sepsis also yielded 
negative results, ruling out the possibility that positive 
staining for CRP observed with the tissue specimens of the 
patients with AMI was merely due to the presence of a 
systemic inflammatory response. Finally, myocardial tis­
sue specimens from an immature child who died in utero 
at 22 weeks' duration of amenorrhea, regarded as a pure, 
nonischemic myocardial control, also did not show any 
staining for CRP.
Deposition of Complement
All tissue specimens were analyzed for the presence of 
activated complement fragments by use o f various MAbs. 
Both C4d (C4-4) and C3d (C3-15) were found to be de­
posited in most infarctions in a pattern reminiscent of that 
of CRP. Figs IB and 2 show an example of deposition of 
C3d in infarcted myocardium at different magnifications. 
The staining patterns of C3c and C4c were similar but less 
distinct than C3d and C4d. Remarkably, C4c and C3c de­
position was more pronounced in infarctions of greater age 
(Table 4). Although this may indicate that most o f  the C4
Fig 2. Positive staining for myofiber elements (sarcolemma, cy­
toplasm, and cross-striation) in infarcted myocardium with MAb 
C3-15 can be recognized in longitudinally cut myofibers (mag­
nification x630) (patient 13, Table 2).
and C3 found at the site of complement activation was in  
the form of C4d and C3d, we cannot exclude the possi­
bility that these observations reflected differences in the 
efficiency of the antibodies to detect each antigen in that 
more C4b or C3b deposition was required to obtain a pos­
itive staining for C4c or C3c than for C4d or C3d> respec­
tively. Another plausible explanation for these observa­
tions, however, might be that only part of the C4 and C3 
deposited consisted of C4b/C4bi and C3b/C3bi, respec­
tively, whereas the majority, in particular in younger in­
farctions, consisted of C4d and C3d. As with CRP, com­
plement depositions were not found in the myocardial 
samples from 1 patient who died within 12 hours after 
AMI symptoms had begun, nor were they detected in myo­
cardial samples from 2 patients at the site of previous 
AMIs from 1 and 10 years previously. In 1 patient with an
T a b le  4. Intensity of Immunostaining of CRP and Complement in 
Myocardial Infarction
Immunostaining
Antigen
Infarct Age
Total (17)
Hours 
(No. of Patients) Days (No. of Patients)
0-12(2) 12-24 (1) 1 -3 (3) 3-5 (3) 5-9 (5) 9-14 (3)
CRP
Myofiber 1/1/0 0/0/1 0/1/2 0/0/3 0/2/3 0/0/3 1 /4/12
Blood vessel 2/0/0 1/0/0 3/0/0 2/0/1 4/0/1 1/1/1 13/1/3
C4d
Myofiber 2/0/0 0/0/1 0/0/3 0/1/2 0/0/5 0/1/2 2/2/13
Blood vessel 1/1/0 0/0/1 1/1/1 1/0/2 2/1/2 0/1/2 5/4/8
C4c
Myofiber 2/0/0 0/0/1 2/1/0 1/0/2 1/1/3 0/0/3 6/2/9
Blood vessel 2/0/0 1/0/0 3/0/0 2/0/1 4/0/1 0/1/2 12/1/4
C3d
Myofiber 1/1/0 0/0/1 0/0/3 0/0/3 0/1/4 0/0/3 1/2/14
Blood vessel 1/1/0 0/0/1 0/0/3 0/0/3 1/0/4 0/0/3 2/1/14
C3c
Myofiber 1/1/0 0/0/1 0/2/0* 1/1/1 0/0/4* 0/1/2 2/5/8
Blood vessel 2/0/0 0/1/0 2/0/0* 2/1/0 3/1/0* 0/1/2 9/4/2
C3a
Myofiber 2/0/0 1/0/0 3/0/0 3/0/0 5/0/0 3/0/0 17/0/0
Blood vessel 2/0/0 1/0/0 3/0/0 3/0/0 5/0/0 3/0/0 17/0/0
Values are number of negative immunostaining/number of moderate but positive immunostaining/number 
of strong, positive immunostaining.
*One slide neglected because of high background staining invalidating proper immunohistochemical scor­
ing procedure.
AMI 0 to 12 hours old, only moderate but significant stain­
ing patterns for complement were found. In concordance 
with the observations for CRP, the complement staining 
was less distinct than that seen in the older infarct samples.
In the infarctions, activated C4 and C3 appeared to be 
localized in the same areas that had fixed CRP (Fig 1A 
and IB). However, these complement fragments were also 
found to be fixed to blood-vessel elements (endothelium, 
intima, tunica media, and adventitia; Table 3). Positive 
cytoplasmic staining for complement was evident in the 
older infarct samples (1 to 14 days old) but was not as 
distinct as that observed for CRP (Fig 2). Significant stain­
ing also seemed to be independent of the presence of PMN 
and/or lymphocyte infiltration.
With respect to deposition of complement, we also in­
cluded a number of controls. First, as with CRP, healthy- 
appearing areas within the infarcted myocardium did not 
stain for complement (see Fig IB). Second, irrelevant 
MAbs (2 IgGl and 1 IgG2a), tested at concentrations sim­
ilar to those for the anti-complement MAbs, yielded neg­
ative results. An MAb against C3a (C3-5) did not stain 
any of the tissue samples from either infarcted or normal 
myocardium (Tables 3 and 4). This was expected, because 
C3a, once formed, is released from C3 and will not remain 
bound to the activator— in our study, myocardial anatomic 
structures. Finally, the myocardial tissue specimens from 
the septic patient and the immature child described above 
did not depict any staining for complement.
Colocalization of CRP and Complement
To test colocalization of CRP and activated complement 
in infarcted myocardium, we performed double-staining 
experiments according to the procedure outlined in 
“Methods.” Fig 3 depicts an example of these experiments 
showing a double immunostaining for CRP (brown) and 
C3d (blue) of infarcted myocardium. The double staining 
of CRP and C4cl showed similar patterns. In general, CRP 
was found to be colocalized with activated C4 and C3 in 
the tissue samples, although in some areas (in particular 
in the cytoplasm of jeopardized cardiomyocytes in infarc­
tion that existed longer than 24 hours), CRP apparently 
was present in larger quantity, as was evident from the 
slightly predominating brown color.
Discussion
Hill and W ard29 were the first to show that complement 
is activated locally by infarcted myocardium. These re­
sults, observed in rats, have been confirmed by a number 
of other studies in various animal models for AM I.1*2’22’23 
In addition, these studies showed that complement acti­
vation in infarcted myocardium occurs via the classic path­
way30-31 and that inhibition of this activation attenuates 
infiltration of the jeopardized myocardium by neutrophils 
and reduces infarct size.!-3’32’33 Thus, complement activa­
tion is a key event mediating the deleterious effects of the 
local inflammatory response occurring in the infarcted 
myocardium. Our results indicate that complement is ac­
tivated in human AMI as well, which agrees with previous 
studies.22-23 The nature of the substance of the infarcted 
myocardium that starts activation of complement by bind­
ing and activating the first component of complement is 
unknown. Some studies suggest that constituents of mi­
tochondrial membranes may act as activators.30-31’34 How­
ever, our results indicate that in human AMI, CRP, an 
acute-phase protein well known for its ability to activate
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Fig 3. Colocalization of CRP and C3d in infarcted myocardium 
(abbreviations as in Fig 1) shown by immunohistochemical dou­
ble staining using MAbs 5G4 (brown) and C3-15 (blue) (magni­
fication X200) (patient 3, Table 2).
the classic complement pathway in vitro,13’15 is involved 
as an activator. Yet, we cannot definitely exclude that other 
substances able to activate complement are generated in 
the infarcted myocardium as well.
The major anatomic structure in the infarcted myocar­
dium that had bound CRP (and complement) was the heart 
muscle cell itself, more specifically the sarcolemma, cy­
toplasm, and cross-striation, in addition to blood-vessel 
elements (Figs 1A, IB, and 2; Tables 3 and 4). Further­
more, positive staining for CRP seemed to be independent 
of the presence of PMN infiltration in the myocardium. 
This localization pattern of CRP is comparable to that de­
scribed in 1963 by Kushner and coworkers,20 using poly­
clonal antibodies in infarcted myocardium of rabbits. In 
other (experimental) inflammatory diseases, CRP has also 
been found deposited at sites of inflammation.17*18 Turn­
over studies with labeled CRP in humans with inflamma­
tory disease, however, have failed to demonstrate local­
ization of this acute-phase protein.35 Thus, the fraction of 
the total amount of CRP that localizes in inflamed tissues 
is apparently small. Our results do not allow conclusions 
regarding the nature of the ligand for CRP in the infarcted 
myocardium. However, considering that CRP can bind to 
vesicles consisting of phosphatidyl choline and lysophos- 
phatidyIcholine13-15 and that on infarction a significant 
amount of lysophospholipids (which are not detectable in 
healthy myocardium) are generated in the myocardium,36 
we consider lysophospholipids likely candidates to serve 
as ligands for CRP.
Involvement of CRP in the local activation of comple­
ment was implied by the observation that fixation of CRP 
and deposition of complement in the infarcted myocar­
dium occurred in an almost identical fashion (Fig 1A and 
IB). Double immunostaining techniques (Fig 3) indeed 
confirmed that CRP and activated complement for the m a­
jor part were localized at similar anatomic sites.
Previously we have shown that MAb C4-1 and MAb 
C3-9 recognize activated C4 and C3, respectively, and not 
native C4 or C3 25-26 and that a similar* specificity holds for 
immunohistochemical applications.37 Therefore, positive 
immunostaining with these MAbs ruled out the possibility 
that the results were influenced by aspecific binding of C4 
and C3 to the infarcted myocardium. However, the epi­
topes recognized by MAb C4-1 and MAb C3-9 are also 
expressed on C3 with a cleaved thioester,25,26 implying that
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positive immunostaining with these MAbs may have been 
due to nonspecific binding of native C4 and C3 to the 
infarcted tissue with subsequent cleavage of the thioester, 
for example due to fixation procedures or storage condi­
tions of the tissue samples. However, this possibility could 
be ruled out by the negative staining with MAb C3-5, 
which recognizes the C3a part of C3 with a  cleaved thioes­
ter.23 Therefore, the depositions of C4 and C3 in the in­
farcted myocardium reflected complement activation and 
not nonspecific binding, in concordance with conclusions 
reached by others.23
Remarkably, although vascular elements clearly ap­
peared to have bound complement activation products 
(C3b/bi/d and C4b/bi/d), they contained only small 
amounts of CRP, if any. Endothelial cells can synthesize 
complement proteins in vitro.33 However, the endothelial 
deposition observed in the patients described here prob­
ably did not reflect synthesis of complement proteins by 
endothelial cells, because two of the MAbs used (C4-1 
and C3-9) are specific for activated C4 or C3, respec­
tively, hardly recognizing the native proteins.25’26 Fur­
thermore, the C3 species fixed to the endothelium did not 
contain detectable C3a, consistent with the proposal that 
this C3 species represented activated C3 and not native 
C3. The presence o f  activated complement components 
on endothelial structures in the absence o f CRP may in­
dicate that molecules other than CRP are involved in ac­
tivating complement in infarcted myocardium. However, 
it cannot be excluded that CRP had dissociated from the 
endothelial structures after having activated complement. 
In agreement with this is the observation that patients 
with AMI have increasing plasma levels of CRP com- 
plexed to activated C3 or C4 (W.K.L., C.A.V., W.T.H., 
G.J.W., C.E.H., unpublished observations). Alternatively» 
the sensitivity of detecting activated complement by im- 
munohistochemistry may have been superior to that of de­
tecting CRP. The presence of moderate amounts of CRP 
bound to endothelial structures in some tissue specimens 
supports this latter notion.
Fixation of CRP or complement was not or was only 
very moderately seen in the tissue samples of a very re­
cent infarction (< 1 2  hours earlier) or those of old infarc­
tion (>1 year earlier). Thus, it is tempting to speculate 
that CRP fixation (as well as complement deposition) in 
human AMI starts within 12 hours, lasts beyond 14 days, 
and decreases with time thereafter. CRP plasma concen­
trations start to rise « 8  to 10 hours after challenge with 
the inciting stimulus,38 for example, myocardial infarc­
tion.5-7*8 The absence of CRP in early infarctions (0 to 12 
hours old), therefore, is not surprising. Moreover, the ab­
sence of complement in the early infarctions, which has 
also been noted in animal models,22*23 supports the theory 
that CRP is a main activator of complement during the 
early phases (12 to 24 hours) of AMI. In agreement, the 
intensity of the staining patterns of CRP and complement 
in the tissue samples of the infarctions both tended to 
increase with the age of the infarction, being optimal at 
3 days. These kinetics of CRP deposition in the myocar­
dium parallel the systemic response of CRP levels, which 
reach a peak after « 7 2  hours and decline thereafter.5 It 
is to be noted that an increase of circulating CRP itself 
was not sufficient to yield localization o f CRP in the myo­
cardium, because in a patient with sepsis we did not de­
tect CRP in the myocardium and the heal thy-appearing 
areas of the infarcted myocardium did not contain de­
tectable CRP. Altogether, our data predict that interven­
tions at the level o f  CRP or complement should be ap­
plied within 12 hours up to 3 days after start of AMI, at 
least in patients not receiving reperfusion therapy.
In conclusion, we show localization of CRP in infarcted 
myocardium. W e suggest that CRP, by activating comple­
ment, enhances inflammation and hence promotes tissue 
damage in AML Moreover, we think that our observations 
might have pathophysiological implications beyond myo­
cardial infarction, because in other inflammatory diseases 
(eg, rheumatoid arthritis, inflammatory bowel disease, sep­
sis, and meningitis), similar CRP and complement re­
sponses are seen. Future studies are warranted to investi­
gate whether this proinflammatory role of CRP may lead 
to new therapeutic approaches in AMI and in other inflam­
matory diseases.
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